ERBB2 and non-small cell lung carcinoma: Examples include the use of imatinib (Gleevec) for chronic myelogenous leukemia, crizotinib and other anaplastic lymphoma kinase (ALK) inhibitors for non-small-cell lung cancers, and trastuzumab and lapatinib for ERBB2/HER2 amplified breast cancers [3–8].